Overview

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, Phase I study of apalutamide in combination with abiraterone acetate, docetaxel and prednisone in patients with metastatic mastrate resistant prostate cancer (mCRPC). This study is designed to determine the dose that apalutamide can be administered safely in combination with abiraterone acetate, docetaxel and prednisone.

Phase:

Phase 1

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborator:

Janssen Scientific Affairs, LLC

Treatments:

Abiraterone Acetate
Docetaxel
Prednisone